Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) is buying Novamind Inc. (CSE: NM) (OTCQB: NVMDF) in an all-stock deal valued at C$26.2 million on a fully diluted in-the-money basis. The combined company will operate 13 wellness clinics and will be positioned as a psychedelic-assisted therapy provider in North America. the company expects revenue of approximately C$10 million in annual pro-forma revenue based on the trailing four quarters.
“Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. The Novamind acquisition presents a transformational opportunity for Numinus to launch a strong U.S. platform through eight established, reputable, efficiently operating and revenue-producing clinics,” says Payton Nyquvest, Founder and CEO, Numinus. “We prioritize working with the best partners in this industry and Novamind’s U.S. market presence, complementary client programming and respected clinical research capabilities allow us to accelerate our strategic growth plans and broaden access to healing and wellness.”
Research To Continue
Numinus‘ executive team and board will remain in place and the combined company will be led by CEO Payton Nyquvest.
The combined company will operate four clinical research sites and a bioanalytical laboratory, all of which are currently supporting leading drug developers in psychedelic medicine with critical infrastructure and services. Select ongoing psychedelic medicine clinical trials include:
- A single-arm, open-label, compassionate access trial for MDMA-assisted therapy that has made significant progress toward treating patients with PTSD hosted in collaboration with MAPS Public Benefit Corporation (MAPS PBC);
- A phase II clinical trial investigating psilocybin for major depressive disorder sponsored by the Usona Institute;
- An open-label compassionate access trial of psilocybin-assisted psychotherapy for substance use disorders;
- A phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder in adults sponsored by MindMed;
Mr. Nyquvest added, “We expect this acquisition will significantly bolster our financial performance, growing Numinus’ annual revenue to more than five times our current levels, and driving meaningful margin improvement through identified operating efficiencies. Our combined capabilities will deliver exceptional value for our clients, employees, and shareholders. We look forward to welcoming the Novamind team to the Numinus family.”